Following Strategic Health Inputs: Brentuximab Vedotin Concentration: 50 Mg, Pharmaceutical Form: Lyophilic Powder For Injection; Acalabrutinib Concentration: 100 Mg; Medicinal Extract Active Ingredient: Cannabidiol Oil, Concentration: 200 Mg/Ml, Pharmaceutical Form: Oral Solution Canabidiol Pratidonaduzzi 200Mg/Ml; And Medicinal Extract Active Ingredient: Cannabidiol Oil, Concentration: 200 Mg/Ml, Pharmaceutical Form: Oral Solution Canabidiol Pratidonaduzzi 200Mg/Ml.

MINISTERIO DA SAUDE - Secretaria Executiva - Subsecretaria de Assuntos Administrativos - Departamento de Logistica Brazil has Released a tender for Following Strategic Health Inputs: Brentuximab Vedotin Concentration: 50 Mg, Pharmaceutical Form: Lyophilic Powder For Injection; Acalabrutinib Concentration: 100 Mg; Medicinal Extract Active Ingredient: Cannabidiol Oil, Concentration: 200 Mg/Ml, Pharmaceutical Form: Oral Solution Canabidiol Pratidonaduzzi 200Mg/Ml; And Medicinal Extract Active Ingredient: Cannabidiol Oil, Concentration: 200 Mg/Ml, Pharmaceutical Form: Oral Solution Canabidiol Pratidonaduzzi 200Mg/Ml. in Pharmaceuticals. The tender was released on Apr 20, 2024.

Country - Brazil

Summary - Following Strategic Health Inputs: Brentuximab Vedotin Concentration: 50 Mg, Pharmaceutical Form: Lyophilic Powder For Injection; Acalabrutinib Concentration: 100 Mg; Medicinal Extract Active Ingredient: Cannabidiol Oil, Concentration: 200 Mg/Ml, Pharmaceutical Form: Oral Solution Canabidiol Pratidonaduzzi 200Mg/Ml; And Medicinal Extract Active Ingredient: Cannabidiol Oil, Concentration: 200 Mg/Ml, Pharmaceutical Form: Oral Solution Canabidiol Pratidonaduzzi 200Mg/Ml.

Deadline - login to view

GT reference number - 81130312

Product classification - Medicinal products for the alimentary tract and metabolism